JPH04235194A - Coal enrichment reaction - Google Patents
Coal enrichment reactionInfo
- Publication number
- JPH04235194A JPH04235194A JP17135390A JP17135390A JPH04235194A JP H04235194 A JPH04235194 A JP H04235194A JP 17135390 A JP17135390 A JP 17135390A JP 17135390 A JP17135390 A JP 17135390A JP H04235194 A JPH04235194 A JP H04235194A
- Authority
- JP
- Japan
- Prior art keywords
- group
- formula
- alkyl
- reaction
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000006243 chemical reaction Methods 0.000 title claims abstract description 28
- 239000003245 coal Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 17
- -1 acrylic ester Chemical class 0.000 claims abstract description 16
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 10
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 8
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims abstract description 6
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims abstract description 6
- 150000004795 grignard reagents Chemical class 0.000 claims abstract description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 4
- 239000007818 Grignard reagent Substances 0.000 claims abstract description 4
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 4
- 125000005448 ethoxyethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims abstract description 4
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims abstract description 4
- 125000002252 acyl group Chemical group 0.000 claims abstract description 3
- 125000003118 aryl group Chemical group 0.000 claims abstract description 3
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims abstract description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 229910052744 lithium Inorganic materials 0.000 claims description 3
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 claims description 2
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 abstract description 5
- 150000003431 steroids Chemical group 0.000 abstract description 5
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 abstract description 4
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 abstract description 3
- 239000004380 Cholic acid Substances 0.000 abstract description 3
- 229960002471 cholic acid Drugs 0.000 abstract description 3
- 235000019416 cholic acid Nutrition 0.000 abstract description 3
- VXWPONVCMVLXBW-UHFFFAOYSA-M magnesium;carbanide;iodide Chemical compound [CH3-].[Mg+2].[I-] VXWPONVCMVLXBW-UHFFFAOYSA-M 0.000 abstract description 2
- XYDYWTJEGDZLTH-UHFFFAOYSA-N methylenetriphenylphosphorane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=C)C1=CC=CC=C1 XYDYWTJEGDZLTH-UHFFFAOYSA-N 0.000 abstract description 2
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 abstract 1
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 21
- 239000000243 solution Substances 0.000 description 19
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- 239000002904 solvent Substances 0.000 description 10
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- 150000001298 alcohols Chemical class 0.000 description 9
- 210000000941 bile Anatomy 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 238000010898 silica gel chromatography Methods 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
- 239000003480 eluent Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 230000001766 physiological effect Effects 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 230000002194 synthesizing effect Effects 0.000 description 3
- NFDXQGNDWIPXQL-UHFFFAOYSA-N 1-cyclooctyldiazocane Chemical compound C1CCCCCCC1N1NCCCCCC1 NFDXQGNDWIPXQL-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000003763 carbonization Methods 0.000 description 2
- 239000007806 chemical reaction intermediate Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000002812 cholic acid derivative Substances 0.000 description 2
- 239000012973 diazabicyclooctane Substances 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 239000012280 lithium aluminium hydride Substances 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 2
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- WXZIKFXSSPSWSR-UHFFFAOYSA-N [Li]CCCCC Chemical compound [Li]CCCCC WXZIKFXSSPSWSR-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- YLKUQAFDYMLBCK-UHFFFAOYSA-N butan-1-ol;ethyl acetate Chemical compound CCCCO.CCOC(C)=O YLKUQAFDYMLBCK-UHFFFAOYSA-N 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
- SIHHLZPXQLFPMC-UHFFFAOYSA-N chloroform;methanol;hydrate Chemical compound O.OC.ClC(Cl)Cl SIHHLZPXQLFPMC-UHFFFAOYSA-N 0.000 description 1
- 239000000731 choleretic agent Substances 0.000 description 1
- 230000001989 choleretic effect Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000006735 epoxidation reaction Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- NNQYFBSGBOKZKP-UHFFFAOYSA-N ethylidene(triphenyl)-$l^{5}-phosphane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=CC)C1=CC=CC=C1 NNQYFBSGBOKZKP-UHFFFAOYSA-N 0.000 description 1
- BLHLJVCOVBYQQS-UHFFFAOYSA-N ethyllithium Chemical compound [Li]CC BLHLJVCOVBYQQS-UHFFFAOYSA-N 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000006197 hydroboration reaction Methods 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- FRIJBUGBVQZNTB-UHFFFAOYSA-M magnesium;ethane;bromide Chemical compound [Mg+2].[Br-].[CH2-]C FRIJBUGBVQZNTB-UHFFFAOYSA-M 0.000 description 1
- UGVPKMAWLOMPRS-UHFFFAOYSA-M magnesium;propane;bromide Chemical compound [Mg+2].[Br-].CC[CH2-] UGVPKMAWLOMPRS-UHFFFAOYSA-M 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- NTNUDYROPUKXNA-UHFFFAOYSA-N methyl 2-(triphenyl-$l^{5}-phosphanylidene)acetate Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=CC(=O)OC)C1=CC=CC=C1 NTNUDYROPUKXNA-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- DVSDBMFJEQPWNO-UHFFFAOYSA-N methyllithium Chemical compound C[Li] DVSDBMFJEQPWNO-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 1
- 150000004965 peroxy acids Chemical class 0.000 description 1
- NHKJPPKXDNZFBJ-UHFFFAOYSA-N phenyllithium Chemical compound [Li]C1=CC=CC=C1 NHKJPPKXDNZFBJ-UHFFFAOYSA-N 0.000 description 1
- ANRQGKOBLBYXFM-UHFFFAOYSA-M phenylmagnesium bromide Chemical compound Br[Mg]C1=CC=CC=C1 ANRQGKOBLBYXFM-UHFFFAOYSA-M 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- LYBIZMNPXTXVMV-UHFFFAOYSA-N propan-2-yl prop-2-enoate Chemical compound CC(C)OC(=O)C=C LYBIZMNPXTXVMV-UHFFFAOYSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-O pyridinium Chemical compound C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 150000004072 triols Chemical group 0.000 description 1
- DDMOZUBZYFKJDS-UHFFFAOYSA-N triphenyl(propylidene)-$l^{5}-phosphane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=CCC)C1=CC=CC=C1 DDMOZUBZYFKJDS-UHFFFAOYSA-N 0.000 description 1
- IIHPVYJPDKJYOU-UHFFFAOYSA-N triphenylcarbethoxymethylenephosphorane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=CC(=O)OCC)C1=CC=CC=C1 IIHPVYJPDKJYOU-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
Description
【発明の詳細な説明】
[産業上の利用分野]
本発明は利胆作用等の医薬品として有用な生理活性を有
する各種の胆汁アルコールを合成するにあたり、合成中
間体を合成するに重要な反応である増炭反応に関するも
のである。[Detailed Description of the Invention] [Industrial Application Field] The present invention is an important reaction for synthesizing synthetic intermediates for synthesizing various bile alcohols having physiological activities useful as choleretic and other pharmaceuticals. This is about a certain carbonization reaction.
[従来の技術および課題]
動物の分泌物は様々な医薬用途を有することはよく知ら
れている。例えば、一次胆汁酸であるコール酸やデオキ
シコール酸は、脂溶性物質の吸収促進、コレステロール
生合成調節、胆汁生成及び分泌等に重要な関与をするこ
とが明らかにされている。これらステロイド骨格を有す
る化合物(以下、胆汁アルコール類という。)を医薬品
として供する場合には、安価かつ大量に製造する必要が
あり、従って、胆汁アルコール類を大量に化学合成する
必要がある。これまでに胆汁アルコール類の合成のため
に数多くの研究がなされており、あらゆる角度からの報
告が行われている。特に胆汁アルコール類の一連の合成
過程においては、ステロイド骨格の側鎖部分の増炭反応
が重要になるが、より高収率かつ、より簡便な増炭反応
の開発が望まれていた。[Prior Art and Problems] It is well known that animal secretions have various medicinal uses. For example, primary bile acids such as cholic acid and deoxycholic acid have been shown to play an important role in promoting the absorption of fat-soluble substances, regulating cholesterol biosynthesis, and bile production and secretion. When these compounds having a steroid skeleton (hereinafter referred to as bile alcohols) are to be used as medicines, they need to be produced at low cost and in large quantities, and therefore it is necessary to chemically synthesize bile alcohols in large quantities. Numerous studies have been conducted to date on the synthesis of bile alcohols, and reports have been made from all angles. Particularly in the series of synthesis processes for bile alcohols, the carbon-enriching reaction of the side chain portion of the steroid skeleton is important, and there has been a desire to develop a simpler carbon-enriching reaction with higher yields.
更に、従来のコール酸誘導体および各種の胆汁アルコー
ルの合成においては、反応中間体自体の溶解性が低く、
かつ使用可能な保護基が制限されているために、合成法
が制限され、収率が悪くなるという問題点もあった。Furthermore, in the conventional synthesis of cholic acid derivatives and various bile alcohols, the solubility of the reaction intermediate itself is low;
Furthermore, since the usable protecting groups are limited, the synthesis method is limited and the yield is poor.
[課題を解決するための手段]
本発明者等は、より高収率かつ、より簡便なステロイド
骨格の側鎖部分の増炭反応を求めて鋭意研究した結果、
アクリル酸エステル化合物、グリニャール試薬、アルキ
ルリチウムまたはウィッティッヒ試薬を作用させること
により、より高収率かつ、より簡便に増炭反応ができる
ことを見いだし本発明を完成した。[Means for Solving the Problems] As a result of intensive research by the present inventors in search of a higher-yield and simpler carbon-enriching reaction of the side chain portion of the steroid skeleton,
The present invention was completed by discovering that a higher yield and simpler carbonization reaction can be carried out by using an acrylic acid ester compound, a Grignard reagent, an alkyl lithium, or a Wittig reagent.
すなわち本発明は、下記式I
(式I中、R1は、アシル基、メトキシメチル基、アル
キル基、シリル基、メトキシエトキシメチル基、水素原
子、エトキシエチル基またはテトラヒドロピラニル基を
示す。)
で表される化合物に、アクリル酸エステル化合物、グリ
ニャール試薬、アルキルリチウムおよびウィッティッヒ
試薬から選ばれるひとつの試薬を作用させて下記式II
[式II中、R2は、下記式III
(式III中、R3は、アルキル基、アリール基または
下記式V
(式V中、R4は、ホルミル基またはアルコキシカルボ
ニル基を示す。)を示す。)または下記式IV−CH=
CH−R5(IV)
(式IV中、R5は、アルキル基、水素原子またはアル
コキシカルボニル基を示す。)を示す。]で表される化
合物を得ることを特徴とする増炭反応(以下本発明の方
法という。)である。That is, the present invention provides the following formula I (in formula I, R1 represents an acyl group, a methoxymethyl group, an alkyl group, a silyl group, a methoxyethoxymethyl group, a hydrogen atom, an ethoxyethyl group, or a tetrahydropyranyl group). The represented compound is reacted with one reagent selected from an acrylic acid ester compound, a Grignard reagent, an alkyl lithium, and a Wittig reagent to form the following formula II [In formula II, R2 is the following formula III (In formula III, R3 is , an alkyl group, an aryl group, or the following formula V (in the formula V, R4 represents a formyl group or an alkoxycarbonyl group) or the following formula IV-CH=
CH-R5(IV) (In formula IV, R5 represents an alkyl group, a hydrogen atom, or an alkoxycarbonyl group.) This is a carbon enrichment reaction (hereinafter referred to as the method of the present invention) characterized by obtaining a compound represented by the following.
以下に本発明を詳細に説明する。The present invention will be explained in detail below.
まず式Iの化合物は、例えばコール酸を原料として、水
酸基をTHP(テトラヒドロピラニル)基で保護し、還
元してメチルエステルをヒドロキシメチルとした後、酸
化することにより得ることができる。ここで水酸基の保
護としてTHP基以外に、メトキシメチル基、メトキシ
エトキシメチル基、エトキシエチル基等の保護基を用い
ることもでき、これにより反応中間体自体の溶解性を高
めることができる。First, the compound of formula I can be obtained by, for example, using cholic acid as a raw material, protecting the hydroxyl group with a THP (tetrahydropyranyl) group, reducing the methyl ester to hydroxymethyl, and then oxidizing it. In addition to the THP group, protecting groups such as methoxymethyl group, methoxyethoxymethyl group, and ethoxyethyl group can be used to protect the hydroxyl group, thereby increasing the solubility of the reaction intermediate itself.
式Iの化合物の製造の具体例を示すと以下の如くである
。A specific example of the preparation of the compound of formula I is as follows.
具体例1
R.B.Moffettらの方法により得たMethy
l−3α,7α,12α−Trihydroxy−5β
−cholan−24−oate(10.0g;
23.7mM)と触媒量のp−Toluene sul
fonic acid mono−hydrate(4
3mg)の塩化メチレン10mlの溶液に、水冷下、撹
拌しながら3,4−Dihydro 2H−Pyran
(41.5ml,45.05g;535mM)の塩化メ
チレン(100ml)溶液を30分間かけて滴加する。Specific example 1 R. B. Methy obtained by the method of Moffett et al.
l-3α,7α,12α-Trihydroxy-5β
-cholan-24-oate (10.0 g; 23.7 mM) and a catalytic amount of p-Toluene sul
fonic acid mono-hydrate (4
3 mg) in 10 ml of methylene chloride, 3,4-Dihydro 2H-Pyran was added while stirring under water cooling.
(41.5ml, 45.05g; 535mM) in methylene chloride (100ml) is added dropwise over 30 minutes.
滴加後、室温で5時間撹はんし、そして、反応液をジエ
チルエーテル400mlで希釈する。抽出液を5%炭酸
水素ナトリウム水溶液150ml、精製水100mlと
飽和食塩水100mlで洗浄したのち、無水硫酸マグネ
シウムで乾燥する。溶媒を減圧下留去後、n−ヘキサン
−酢酸エチル(3:1)を溶出溶媒とするシリカゲルカ
ラムクロマトグラフィーにより生成物を精製した。生成
物、Methyl 3α,7α,12α−Tritet
rahydropyranoxy−5β−
cholan−24−oateは、淡黄色の油状物質で
ある。After the dropwise addition, the mixture was stirred at room temperature for 5 hours, and the reaction solution was diluted with 400 ml of diethyl ether. The extract is washed with 150 ml of 5% aqueous sodium bicarbonate solution, 100 ml of purified water, and 100 ml of saturated saline, and then dried over anhydrous magnesium sulfate. After evaporating the solvent under reduced pressure, the product was purified by silica gel column chromatography using n-hexane-ethyl acetate (3:1) as an eluent. Product, Methyl 3α,7α,12α-Tritet
rahydropyranoxy-5β-cholan-24-oate is a pale yellow oily substance.
(収量15.03g,収率94.13%)次に、窒素気
流下、水冷しながら水素化リチウムアルミニウム(6.
0g;158mM)の無水テトラヒドロフラン(250
ml)の撹拌して懸濁させた溶液に、化合物Methy
l 3α,7α,12α−Tritetrahydro
pyranoxy−
5β−cholan−24−oate(16.2g;2
3.3mM)の無水テトラヒドロフラン(50ml)溶
液を30分かけて滴下する。反応液を、徐々に室温に戻
したのち、5時間加熱還流する。(Yield 15.03 g, yield 94.13%) Next, lithium aluminum hydride (6.
0g; 158mM) of anhydrous tetrahydrofuran (250
ml) of the compound Methy.
l 3α, 7α, 12α-Tritetrahydro
pyranoxy-5β-cholan-24-oate (16.2g; 2
A solution of 3.3 mM) in anhydrous tetrahydrofuran (50 ml) was added dropwise over 30 minutes. After the reaction solution is gradually returned to room temperature, it is heated under reflux for 5 hours.
放冷後、反応溶液を0.7規定塩酸300mlに注意深
く注ぎ、生成物を酢酸エチル600mlで抽出する。得
られた有機層を1規定塩酸100ml、飽和炭酸水素ナ
トリウム水溶液100ml、精製水100ml、飽和食
塩水100mlで洗浄し、無水硫酸マグネシウムで乾燥
させる。溶媒を減圧下留去したのち、残査をn−ヘキサ
ン−酢酸エチル(4:1)の溶出溶媒によるシリカゲル
カラムクロマトグラフィーにより精製した。生成物、3
α,7α,12α−性油状物質として得た。After cooling, the reaction solution was carefully poured into 300 ml of 0.7N hydrochloric acid, and the product was extracted with 600 ml of ethyl acetate. The obtained organic layer is washed with 100 ml of 1N hydrochloric acid, 100 ml of saturated aqueous sodium bicarbonate solution, 100 ml of purified water, and 100 ml of saturated brine, and dried over anhydrous magnesium sulfate. After the solvent was distilled off under reduced pressure, the residue was purified by silica gel column chromatography using n-hexane-ethyl acetate (4:1) as an eluent. product, 3
Obtained as an α,7α,12α-based oil.
ol(6.47g;10.0mM)とピリジニウムジク
ロロメート(5.20g;15mM)を含む無水塩化メ
チレン100ml溶液を、室温で12時間撹拌する。反
応液を塩化メチレン50mlで希釈したのち、吸引濾過
する。濾波を25℃で減圧濃縮する。残渣をn−ヘキサ
ン−酢酸エチル(7:3)を溶出溶媒とするシリカゲル
カラムクロマトグラフィーにより精製し、無色の油状物
質、更に、式Iの化合物は目的化合物に応じて適宜置換
基を換えることにより得ることができる。A solution of 100 ml of anhydrous methylene chloride containing ol (6.47 g; 10.0 mmol) and pyridinium dichloromate (5.20 g; 15 mmol) is stirred at room temperature for 12 hours. The reaction solution was diluted with 50 ml of methylene chloride, and then filtered with suction. Concentrate the filter under reduced pressure at 25°C. The residue was purified by silica gel column chromatography using n-hexane-ethyl acetate (7:3) as an eluent to obtain a colorless oil.Furthermore, the compound of formula I was obtained by changing the substituents as appropriate depending on the target compound. Obtainable.
次に本発明で用いるアクリル酸エステル化合物の具体例
としてはアクリル酸メチル、アクリル酸エチル、アクリ
ル酸イソプロピル等が挙げられる。反応時の溶媒として
はジアザビシクロオクタン(DABCO)を用いること
ができ、0℃〜室温の温度条件下で1〜4週間反応させ
る。Next, specific examples of the acrylic ester compound used in the present invention include methyl acrylate, ethyl acrylate, and isopropyl acrylate. Diazabicyclooctane (DABCO) can be used as a solvent during the reaction, and the reaction is carried out for 1 to 4 weeks at a temperature of 0° C. to room temperature.
グリニャール試薬の具体例としては、メチルマグネシウ
ムヨージド、エチルマグネシウムプロミド、プロピルマ
グネシウムプロミド、フェニルマグネシウムプロミド等
が挙げられる。反応時の溶媒としてはエーテル、テトラ
ヒドロフラン等を用いることができ、室温以下の温度条
件下で0.5〜30時間反応させる。Specific examples of Grignard reagents include methylmagnesium iodide, ethylmagnesium bromide, propylmagnesium bromide, phenylmagnesium bromide, and the like. Ether, tetrahydrofuran, etc. can be used as a solvent during the reaction, and the reaction is carried out at a temperature below room temperature for 0.5 to 30 hours.
アルキルリチウムの具体例としては、メチルリチウム、
フェニルリチウム、エチルリチウム、ブチルリチウム、
ペンチルリチウム、シクロヘキシルリチウム、2−リチ
ウム−3,3−ジエトキシプロペン等が挙げられる。反
応時の溶媒としてはエーテル、テトラヒドロフラン等を
用いることができ、室温以下の温度条件下で0.5〜5
0時間反応させる。Specific examples of alkyllithium include methyllithium,
Phenyllithium, ethyllithium, butyllithium,
Examples include pentyllithium, cyclohexyllithium, 2-lithium-3,3-diethoxypropene, and the like. Ether, tetrahydrofuran, etc. can be used as a solvent during the reaction, and 0.5 to 5
React for 0 hours.
ウイッテイッヒ試薬の具体例としては、メチレントリフ
ェニルホスホラン、エチリデントリフェニルホスホラン
、プロピリデントリフェニルホスホラン、メトキシカル
ボニルメチレントリフェニルホスホラン、エトキシカル
ボニルメチレントリフェニルホスホラン等が挙げられる
。反応時の溶媒としてはエーテル、テトラヒドロフラン
、ベンゼン、トルエン、アルコール類等を用いることが
でき、0℃〜使用する溶媒の沸点以下の温度条件下で0
.5〜30時間反応させる。Specific examples of the Wittig reagent include methylenetriphenylphosphorane, ethylidenetriphenylphosphorane, propylidenetriphenylphosphorane, methoxycarbonylmethylenetriphenylphosphorane, ethoxycarbonylmethylenetriphenylphosphorane, and the like. As a solvent for the reaction, ether, tetrahydrofuran, benzene, toluene, alcohols, etc. can be used, and the
.. Allow to react for 5 to 30 hours.
以上の如くして得られた化合物は、医薬品として有用な
生理活性を有す各種の胆汁アルコールを合成する上で非
常に重要な中間体であり、適宜必要に応じて、再結晶、
シリカゲル等を用いたカラムクロマトグラフィー等の精
製手段を用いて精製することができる。The compounds obtained as described above are very important intermediates in the synthesis of various bile alcohols that have physiological activities useful as pharmaceuticals.
It can be purified using purification means such as column chromatography using silica gel or the like.
[発明の効果]
本発明によれば、医薬品として有用な胆汁アルコール類
の一連の合成過程、とりわけステロイド骨格の側鎖部分
の増炭反応を、より高収率かつ、より簡便に行う事がで
き、しいては医薬品開発の観点からも開発促進に繋がる
という効果が奏される。更に、本発明の方法によって得
られる化合物の反応時における溶解性は良好であること
より、医薬品として生理活性を有するコール酸誘導体を
安価で提供するうえで大きなメリットである。[Effects of the Invention] According to the present invention, a series of synthetic processes for bile alcohols useful as pharmaceuticals, particularly the carbon enrichment reaction of the side chain portion of the steroid skeleton, can be carried out in a higher yield and more easily. In addition, from the viewpoint of drug development, it is effective in promoting development. Furthermore, the compound obtained by the method of the present invention has good solubility during reaction, which is a great advantage in providing cholic acid derivatives having physiological activity as pharmaceuticals at low cost.
以下に実施例を示して本発明を更に詳しく説明するが、
本発明はこれにより何ら制限されるものではない。The present invention will be explained in more detail with reference to Examples below.
The present invention is not limited to this in any way.
実施例1
具体例1で得た3α,7α,12α−
(2.0mM)をアクリル酸メチル(1.86g;20
.0mM)に溶解したのち、反応容器をガラス栓で密栓
し、室温下、遮光しながら3週間撹拌する。反応溶液を
酢酸エチル150ml、飽和食塩水150mlで洗浄後
、無水硫酸マグネシウムで乾燥させる。溶媒を減圧下留
去したのち、残渣をn−ヘキサン、酢酸エチル(5:2
)の溶出溶媒を用いたシリカゲルカラムクロマトグラフ
ィーにより精製したところ無色油状物質として生成物M
ethyl 3α,7α,12α−実施例2
−70℃の条件下で、2−Bromo−3,3−die
thoxy−propene(4.2g;20mM)の
無水テトラヒドロフラン(160ml)溶液にn−ブチ
ルリチウム1M溶液22ml(22mM)を注意深く滴
下し、1時間撹拌した。Example 1 3α,7α,12α- (2.0mM) obtained in Example 1 was mixed with methyl acrylate (1.86g; 20
.. After dissolving the mixture to 0mM), the reaction vessel was tightly closed with a glass stopper, and the mixture was stirred at room temperature for 3 weeks while shielding from light. The reaction solution is washed with 150 ml of ethyl acetate and 150 ml of saturated brine, and then dried over anhydrous magnesium sulfate. After evaporating the solvent under reduced pressure, the residue was diluted with n-hexane and ethyl acetate (5:2).
) was purified by silica gel column chromatography using an eluent of
ethyl 3α,7α,12α-Example 2 Under conditions of -70°C, 2-Bromo-3,3-die
To a solution of thoxy-propene (4.2g; 20mM) in anhydrous tetrahydrofuran (160ml) was carefully added dropwise 22ml of a 1M solution of n-butyllithium (22mM), and the mixture was stirred for 1 hour.
この溶液に具体例1で得た3α,7α,12α−al(
12.9g;20mM)を含む無水テトラヒドロフラン
溶液160mlを加え、反応させた。反応後室温に戻し
、これを注意深く0.25規定硫酸水溶液に注ぎ、更に
酢酸エチル200mlで抽出して3α,7α,12α−
13.8g(98.5%)を得た。Add 3α, 7α, 12α-al obtained in Example 1 to this solution (
160 ml of anhydrous tetrahydrofuran solution containing 12.9 g (20 mM) was added and reacted. After the reaction, the temperature was returned to room temperature, the mixture was carefully poured into a 0.25 N sulfuric acid aqueous solution, and further extracted with 200 ml of ethyl acetate to obtain 3α, 7α, 12α-
13.8g (98.5%) was obtained.
本発明によって得られる式(II)で表される化合物を
、必要により脱保護した後ヒドロボレーションまたはエ
ポキシ化の後還元することにより、医薬品として特に有
用な3α,7α,12α,24,26,27−ヘキサ
ヒドロキシ−5β−コレスタンに変換することができる
。ヒドロボレーションおよび還元は上述したと同様の方
法で行うことができ、エポキシ化は過酸で処理する通常
の方法により行うことができる。The compound represented by the formula (II) obtained by the present invention is optionally deprotected, hydroborated or epoxidized, and then reduced to produce 3α, 7α, 12α, 24, 26, It can be converted to 27-hexahydroxy-5β-cholestane. Hydroboration and reduction can be carried out in the same manner as described above, and epoxidation can be carried out by conventional methods of treatment with peracids.
式(II)で表される化合物からトリオール体への合成
方法の具体例を参考例として以下に示す。A specific example of a method for synthesizing a triol form from the compound represented by formula (II) is shown below as a reference example.
参考例1
実施例2で得た3α,7α,12α−
cholestane−26−al 13.8g(19
.8mM)をメタノールに溶解し、活性化したDowe
x50W−X8と混合して24時間撹はんし、脱保護を
行った。次いでDowex50W−X8を除去し、溶媒
を除去した残渣にテトラヒドロフラン200mlを加え
、1Mボリン−テトラヒドロフラン溶液200ml(2
00mM)を滴下し、6時間撹はんした。反応終了後、
精製水60mlを加え、更に3M水酸化ナトリウム水溶
液40mlを加え撹はんした後、30%過酸化水素水4
8mlを加えて更に反応させた。反応終了後、生成物を
酢酸エチル−n−ブタノール(1:1)で抽出し、クロ
ロホルム−メタノール、水(60:20:8)の下層を
溶媒としたシリカゲルカラムクロマトグラフィーに付し
て精製し、5.6g(60.4%)を得た。Reference Example 1 13.8 g (19
.. 8mM) was dissolved in methanol and activated Dowe
x50W-X8 and stirred for 24 hours to perform deprotection. Next, Dowex 50W-X8 was removed, 200 ml of tetrahydrofuran was added to the residue after removing the solvent, and 200 ml of 1M borine-tetrahydrofuran solution (2
00mM) was added dropwise and stirred for 6 hours. After the reaction is complete,
Add 60 ml of purified water, then add 40 ml of 3M sodium hydroxide aqueous solution and stir, then add 4 ml of 30% hydrogen peroxide solution.
8 ml was added and further reacted. After the reaction, the product was extracted with ethyl acetate-n-butanol (1:1) and purified by silica gel column chromatography using the lower layer of chloroform-methanol and water (60:20:8) as the solvent. , 5.6g (60.4%) was obtained.
参考例2
実施例1で得た3α,7α,12α−
液に、塩化メチレンに溶解したm−
chloroperbenzoic acid 1.0
9g(5mM)を徐々に加えた。次に反応液を、5%炭
酸水素ナトリウム溶液に注ぎ、有機溶媒層より生成物を
得た。この生成物をテトラヒドロフラン20mlに溶解
し、窒素気流下、氷冷した状態で水素化リチウムアルミ
ニウム935mg(25mM)を含むテトラヒドロフラ
ン懸濁液を滴下した。その後5時間加熱還流し、0.7
規定塩酸溶液に注ぎ、生成物を酢酸エチルで抽出し、こ
れを更にメタノール中、活性化したDowex50W−
X8で処理し、次いでクロロホルム−メタノール−水(
60:20:5)の下層を溶媒としたシリカゲルカゲル
カラムクロマトグラフィーに付して精製し、1.68g
(71.8%)を得た。Reference Example 2 m-chloroperbenzoic acid 1.0 dissolved in methylene chloride was added to the 3α, 7α, 12α-solution obtained in Example 1.
9g (5mM) was added slowly. Next, the reaction solution was poured into a 5% sodium hydrogen carbonate solution, and a product was obtained from the organic solvent layer. This product was dissolved in 20 ml of tetrahydrofuran, and a tetrahydrofuran suspension containing 935 mg (25 mM) of lithium aluminum hydride was added dropwise to the solution under ice-cooling under a nitrogen stream. After that, heating under reflux for 5 hours, 0.7
Pour into normal hydrochloric acid solution, extract the product with ethyl acetate, and add to activated Dowex 50W-
X8, then chloroform-methanol-water (
The lower layer (60:20:5) was purified by silica gel column chromatography using a solvent, and 1.68 g
(71.8%).
Claims (1)
キル基、シリル基、メトキシエトキシメチル基、水素原
子、エトキシエチル基またはテトラヒドロピラニル基を
示す。) で表される化合物に、アクリル酸エステル化合物、グリ
ニャール試薬、アルキルリチウムおよびウィッティッヒ
試薬から選ばれるひとつの試薬を作用させて下記式II [式II中、R2は、下記式III (式III中、R3は、アルキル基、アリール基または
下記式V (式V中、R4は、ホルミル基またはアルコキシカルボ
ニル基を示す。)を示す。)または下記式IV−CH=
CH−R5(IV) (式IV中、R5は、アルキル基、水素原子またはアル
コキシカルボニル基を示す。)を示す。]で表される化
合物を得ることを特徴とする増炭反応。[Claims] The following formula I (In formula I, R1 represents an acyl group, a methoxymethyl group, an alkyl group, a silyl group, a methoxyethoxymethyl group, a hydrogen atom, an ethoxyethyl group, or a tetrahydropyranyl group.) The compound represented by is reacted with one reagent selected from an acrylic acid ester compound, a Grignard reagent, an alkyl lithium, and a Wittig reagent to form the following formula II [In formula II, R2 is the following formula III (In formula III, R3 represents an alkyl group, an aryl group, or the following formula V (in formula V, R4 represents a formyl group or an alkoxycarbonyl group) or the following formula IV-CH=
CH-R5(IV) (In formula IV, R5 represents an alkyl group, a hydrogen atom, or an alkoxycarbonyl group.) ] A carbon enrichment reaction characterized by obtaining a compound represented by:
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP17135390A JPH04235194A (en) | 1990-06-30 | 1990-06-30 | Coal enrichment reaction |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP17135390A JPH04235194A (en) | 1990-06-30 | 1990-06-30 | Coal enrichment reaction |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH04235194A true JPH04235194A (en) | 1992-08-24 |
Family
ID=15921626
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP17135390A Pending JPH04235194A (en) | 1990-06-30 | 1990-06-30 | Coal enrichment reaction |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH04235194A (en) |
-
1990
- 1990-06-30 JP JP17135390A patent/JPH04235194A/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH09118641A (en) | Intermediate of 19-nor-vitamin D compound and method for producing the same | |
JPS5854160B2 (en) | Method for producing 1α,3β-dihydroxysteroid-5-ene or its derivative | |
US4554105A (en) | Process for the preparation of 1-hydroxylated vitamin D compounds | |
JPH09328498A (en) | Production of 24,25-dihydroxycholesterol and its synthetic intermediate | |
Kotikalapudi et al. | Gold (I) catalysed cycloisomerisation of β-hydroxy propargylic esters to dihydropyrans/2H-pyrans via allene intermediates | |
JPS6246556B2 (en) | ||
Okuma et al. | One-pot synthesis of enantiomerically pure (methylenecyclopropyl) carbinol: a key intermediate to the synthesis of the causative agent of Jamaican vomiting sickness | |
JPH04235194A (en) | Coal enrichment reaction | |
JP2517743B2 (en) | Production method of optically active alcohol | |
JP2590796B2 (en) | Preparation of hydroxycyclopentanones | |
JPH0140813B2 (en) | ||
JP3446225B2 (en) | Cyclopentane derivative and method for producing the same | |
JP3712077B2 (en) | Hydroindan-4-ol derivative and method for producing the same | |
JP2536516B2 (en) | Hydroxycyclopentanones | |
JPS62175496A (en) | Steroid compound and production thereof | |
WO2005051903A1 (en) | Vitamin d-derived monohalogenovinyl compounds | |
JP3228486B2 (en) | Hydroxyketone derivative and method for producing the same | |
CN105399714B (en) | A kind of new method of asymmetric syntheses natural products () Euscapholide isomers | |
JPS6348269B2 (en) | ||
CN113292630A (en) | Method for asymmetrically synthesizing Triptonide and Triptolide | |
JPS6049640B2 (en) | Method for producing cholesta-5,23,24-trien-3β-ols | |
JPS6034961A (en) | Synthetic intermediate for labeled mevalonic acid and production of labeled mevalonic acid | |
JPS6345385B2 (en) | ||
JPH03118391A (en) | Production of steroid derivative | |
JPS6144879B2 (en) |